OncoVerity

CO - DenverBiotechnology1 H-1B visas (FY2023)

Focus: OncoVerity is a Series A monoclonal antibody biotech focused on oncology, specifically acute myeloid leukemia. The company is pre-revenue and headquartered in Denver, Colorado.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

SERIES A

Open Jobs

About OncoVerity

AI assessmentNot Hiring

No open roles listed right now. Follow OncoVerity to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Cusatuzumab

Leukemia, Myeloid, Acute

Phase 1

Cusatuzumab

Leukemia, Myeloid, Acute

Phase 1

ARGX-110

Help build intelligence for OncoVerity

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at Series A stage with potential for significant equity upside if pipeline executes
Focused portfolio in high-value oncology space (AML) with multiple monoclonal antibody programs addressing large unmet need
Early-stage environment enables cross-functional influence and accelerated skill development across drug development

Watch Out For

Zero active job openings and minimal hiring activity signal current team is lean and growth trajectory uncertain
Only 1 active clinical trial across entire pipeline indicates very early stage with years before meaningful value inflection
Pre-revenue status with unknown funding and cash position creates inherent runway risk typical of Series A biotechs

Generated by Claude from OncoVerity's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ARGX-110

Neoplasms

Phase 1/2

Azacitidine

Leukemia, Myeloid, Acute

Phase 2

Cusatuzumab

Leukemia, Myeloid, Acute

Phase 2

Clinical Trials (1)

NCT06384261A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub